Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.


  • Registration for new subscribers will open in September 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Veterinary Forum December 2009 (Vol 26, No 12)

Insulin receives FDA approval

    ST. JOSEPH, MO—Boehringer Ingelheim Vetmedica Inc. (BIVI) has announced that ProZinc (protamine zinc recombinant human insulin) has been approved for veterinary use by the FDA. ProZinc is an aqueous protamine zinc (PZI) suspension of recombinant human insulin that is used to reduce hyperglycemia in cats with diabetes mellitus.

    According to Kurt Peterson, DVM, technical veterinarian with BIVI, ProZinc is the first recombinant human PZI insulin available for the management of feline diabetes mellitus. "Extensive research has demonstrated that ProZinc is safe and effective for controlling hyperglycemia in newly diagnosed cats and diabetic cats that have not responded well to previous treatment therapies.1"

    In addition, Peterson said the research shows that ProZinc provides consistent absorption with long duration of action, which results in consistent and predictable blood glucose control in diabetic cats.1

    "Because ProZinc is a protamine zinc recombinant human insulin, it offers some key advantages. First, recombinant technology is not subject to the raw material sourcing challenges seen with animal-source insulin products. Second, the protamine and zinc formulation of ProZinc provides a long duration of effect."

    Practitioners and cat owners who have used PZI-VET in the past should find this product to be comparable in potency, onset, and duration of glycemic control.2

    ProZinc should be administered with a U-40 insulin syringe and has an initial recommended dose range of 0.1-0.3 IU insulin/lb of body weight every 12 hours. ProZinc will be available for sale to veterinarians beginning Nov. 16, 2009. Veterinarians should contact their distributor or BIVI representative for more details and product availability. For more information, visit www.ProZinc.us.

    1. Nelson RW, Henley K, Cole C. Field Safety and Efficacy of PZIR for Treatment of Diabetes Mellitus in Cats. JVIM. 2009;23:787-793.

    2. Norsworthy GD, Lynn R, Cole C. Preliminary Study of Protamine Zinc Recombinant Insulin for the Treatment of Diabetes Mellitus in Cats. Vet Ther. 2009;10:24-28.

    References »

    NEXT: LSART rescues horse from rising flood waters


    Did you know... Serotonin syndrome has been documented in monkeys, rats, rabbits, dogs, and humans.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More